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The N-terminus of cMyBP-C can activate actomyosin interactions in the absence of Ca2+, but it is unclear which domains are
necessary. Prior studies suggested that the Pro-Ala rich region of human cMyBP-C activated force in permeabilized human
cardiomyocytes, whereas the C1 and M-domains of mouse cMyBP-C activated force in permeabilized rat cardiac trabeculae.
Because the amino acid sequence of the P/A region differs between human and mouse cMyBP-C isoforms (46% identity), we
investigated whether species-specific differences in the P/A region could account for differences in activating effects. Using chimeric
fusion proteins containing combinations of human and mouse C0, Pro-Ala, and C1 domains, we demonstrate here that the human
P/A and C1 domains activate actomyosin interactions, whereas the same regions of mouse cMyBP-C are less effective. These results
suggest that species-specific differences between homologous cMyBP-C isoforms confer differential effects that could fine-tune
cMyBP-C function in hearts of different species.
1. Introduction
Myosin binding protein-C (MyBP-C) is a regulatory and
structural protein associated with the A-bands (thick fila-
ments) of vertebrate striated muscle sarcomeres. Regulatory
effects are mediated in part by the N-terminus of cardiac
cMyBP-C, which is made up of modular immunoglobulin-
(Ig-) like domains, termed C0 at the N-terminus, followed
by domains C1 through C10 (Figure 1(a)). Between the C0
and C1 domains there is a sequence of ∼50 amino acids that
contains a high percentage of proline and alanine residues
(referred to as the Pro-Ala rich region (P/A)). Between the C1
and C2 domains there is a stretch of ∼100 highly conserved
amino acids referred to as MyBP-C motif or M-domain. The
M-domain is phosphorylated by β-adrenergic agonists and
phosphorylation increases the rate of cross-bridge cycling
[1], thereby contributing to increased inotropic responses of
the heart [2]. Phosphorylation reduces binding of the M-
domain to actin [3] and myosin S2 in vitro [4], but the
precise mechanism(s) by which phosphorylation accelerates
actomyosin interactions is not well understood.
In efforts to uncover mechanisms by which the N-
terminus of cMyBP-C affects cross-bridge cycling several
groups have investigated the effects of recombinant proteins
containing N-terminal cMyBP-C domains on actomyosin
interactions. For instance, Razumova et al. [5] investigated
effects of N-terminal domains in in vitro motility assays
and found that recombinant proteins containing the C1
through C2 domains of mouse cMyBP-C (referred to as
C1C2, inclusive of the M-domain) could activate thin
filament motility even in the absence of Ca2+. Incubation
of permeabilized rat trabeculae with C1C2 also increased
Ca2+ sensitivity of force and increased the rate of tension
redevelopment (ktr) [6]. The activating effects of C1C2
were attributed to the combined effects of the C1 and M-
domains because these domains together were necessary
and sufficient to increase Ca2+ sensitivity of force, whereas
other domains including the C0, P/A, and C1 domains had
little, if any, effect on force activation. However, in apparent
contrast to these results, Herron et al. [7] found that a
recombinant protein comprised of the human C0, P/A, and
C1 domains (i.e., C0C1) activated tension and increased
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Figure 1: Schematic of full-length cMyBP-C, domain boundaries, and recombinant chimeric mouse and human C0C1 proteins. (a)
Schematic of full-length cMyBP-C. The Pro-Ala rich region is denoted by a box between the C0 and C1 domains. (b) Amino acid sequence
alignment of mouse and human C0, P/A, and C1 domains. Arrows indicate domain boundaries. Asterisks denote identical residues. (c)
Schematic of recombinant chimeric proteins used in this study. Squares represent human domains; circles represent mouse domains.
ktr in permeabilized myocytes from human myocardium,
whereas C1C2 (which lacked the P/A region) had no effect.
These authors concluded that the P/A rich region was
required to activate tension and increase ktr.
A potential explanation for the different conclusions
reached in the two studies is that species-specific differences
are responsible for the different functional effects observed
for the mouse versus human proteins. Consistent with
this idea, the full-length cMyBP-C protein is quite similar
between mouse and human isoforms (89% identity, Table 1)
and the C1, M, and C2 domains are highly conserved (>90%
identity), but domains near the N-terminus show greater
sequence divergence with 81% and 46% identity in the C0
domain and P/A regions, respectively (Figure 1(b)). The
large difference in sequence homology in the P/A region
is primarily due to differences in the content of proline
and alanine residues: in the human P/A region, proline and
alanine account for 51% of the sequence, while the mouse
isoform contains only 28% proline and alanine. Interestingly,
a similar trend was noted for a P/A rich sequence in fast
skeletal myosin essential light chains (ELC1) where Bicer and
Reiser [8] found that P/A content scaled with mammalian
size.
The purpose of the present study was to determine
whether species-specific differences in the P/A rich regions
of human and mouse cMyBP-C can account for functional
differences in the ability of recombinant proteins from the
two species to activate actomyosin interactions. Results show
that both the human P/A rich region and the C1 domains
can activate actomyosin interactions, whereas the mouse
P/A and C1 domains are less effective. These results thus
reconcile apparently disparate experimental results and raise
the possibility that species-specific variations in cMyBP-C
regulatory domains contribute to cross-species variations in
cardiac function.
2. Methods
2.1. Protein Cloning, Expression, and Purification. The
recombinant mouse protein mC0C1 (containing the C0, P/A,
and C1 domains, Figure 1(c)) was subcloned from a full-
length mouse cDNA (GenBank gi:3747133), expressed in
M15 cells, and purified using Ni-NTA affinity chromatogra-
phy as previously described [5]. Recombinant human hC0C1
was cloned from a human cDNA obtained by RT-PCR
from whole heart human total RNA (Stratagene, La Jolla,
CA) using a one-step RT-PCR kit (Invitrogen, Carlsbad,
CA). A PCR product encoding hC0C1 was generated using
gene specific primers flanking the desired domains (forward
primer 5′-GGCCCATATGCCTGAGCCGGGGAAGAAG-
3′, reverse primer 5′-GGCCAAGCTTTCATCCGGTGC-
CCATGGCCTCGTG-3′) and cloned into the pQE-2 expres-
sion vector (Qiagen, Valencia, CA) using NdeI and HindIII
restriction sites on the upstream and downstream primers,
respectively. Expression and purification of hC0C1 were
as described previously [5]. Protein concentrations were
determined by measuring light absorbance at 280 nm (cor-
rected for turbidity at 310 nm) using extinction coefficients
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Table 1: Sequence identity between domains of human and mouse
cMyBP-C.
Protein or Domain
Number of Amino Acids
Percent Identity
Mouse Human
cMyBP-C 1270 1274 89
C0C2 447 451 84
C0 104 101 81
Pro-Ala 46 51 46
C1 111 111 90
M 105 107 91
C2 81 81 96
calculated from Swiss Institute for Bioinformatics software
[9].
2.2. Engineered Chimeric C0C1 Proteins. The In-Fusion PCR
Cloning System (Clontech, Mountain View, CA) was used
according to manufacturer’s instructions and the protocol by
Zhu et al. [10] to create seamless chimeric C0C1 proteins
consisting of various combinations of mouse and human
C0, P/A, and C1 domains. Boundaries of the C0, P/A,
and C1 domains are shown in Figure 1(b) and were as
described by Gautel et al. [11] and as listed for human
and mouse cMyBP-C on the Universal Protein Resources
Databank (UniProt) [12]. PCR products encoding the mouse
and human domains were amplified from mouse and human
cMyBP-C cDNA with additional 15 bp flanking sequences at
the 5′ and 3′ ends that overlap with the adjacent segment of
the construct (Table 2, Figure 1(c)). The pQE-2 expression
vector (Qiagen) was digested with NdeI and HindIII and gel-
purified. PCR products and the digested pQE-2 vector were
mixed at a 1 : 2 : 2 : 2 molar ratio with the In-Fusion enzyme
according to manufacturer’s instructions and transformed
into Top10 cells (Invitrogen). Correctly ligated plasmids
were chosen after selection with carbenicillin and sequences
were verified by DNA sequencing at the UC Davis DNA
Sequencing Facility. Selected clones were transformed into
M15 cells for expression and purification as described
previously [5]. Chimeric C0C1 proteins used in this study
are shown schematically in Figure 1(c).
2.3. Native Protein Purification. Heavy meromyosin (HMM)
and S1 were prepared from rabbit psoas skeletal myosin via
α-chymotryptic digest as described [13]. Bovine cardiac F-
actin, tropomyosin, and troponin were purified from ether
powder as described [14–16]. Thin filaments, comprised
of F-actin and regulatory proteins, were reconstituted in
AB buffer (in mmol/L: 25 KCl, 25 imidazole (pH 7.4),
4 MgCl2, 1 EGTA, and 1 DTT) by combining at an
actin:tropomyosin:troponin ratio of 4 : 1 : 1 for in vitro
motility assays and at 7 : 2 : 2 for ATPase assays. The thin fila-
ment mix was labeled with rhodamine-phalloidin according
to Homsher et al. [17] and used in in vitro motility assays.
2.4. Mechanical Force Measurements. Treatment of all ani-
mals was in strict accordance with guidelines and protocols
established by the University of California Institutional
Animal Care and Use Committee. Male Sprague-Dawley
rats (200–250 g) were euthanized by intraperitoneal injection
of sodium pentobarbital. Hearts were then rapidly excised
and right ventricles were dissected in a Ringer’s solution
at pH 7.4 (in mmol/L: 100 NaCl, 24 NaHCO3, 2.5 KCl,
1 MgSO4, 1 Na2HPO4, and 1 CaCl2). Trabeculae were
permeabilized in situ by incubation of splayed ventricles
overnight in a relaxing solution containing 50% glycerol
and 1% Triton X-100 (Sigma, St. Louis, Missouri) at 4◦C.
Individual trabeculae were dissected free from ventricle walls,
pinned to the bottom of a sylgar-coated Petri dish, and
stored for up to one week in glycerinated relaxing solution
at −20◦C.
Steady state force and rate of tension redevelopment (ktr)
measurements were performed as previously described [6].
Briefly, permeabilized trabeculae were mounted between a
force transducer (model 403A, Aurora Scientific Inc.) and
a torque motor (Model 312-Cl, Aurora Scientific Inc). Sar-
comere length was adjusted to ∼2.3 μm in relaxing solution
and monitored throughout the course of the experiment
using an inverted microscope (Olympus IX-71) fitted with
a 12-Mega pixel digital camera (Olympus DP70). Relaxing,
preactivating, and Ca2+-activating solutions were prepared
as previously described using a custom software package [18,
19]. Solutions were maintained at 0.18 M ionic strength and
pH 7.0 at 15◦C (in mmol/L: 15 phosphocreatine, 15 EGTA, at
least 40 MOPS, 1 free Mg2+, 135 Na+ + K+, 1 DTT, 250 units
ml−1 creatine kinase (CK), and 5 ATP). Ca2+ concentration
(reported as pCa = −log[Ca2+]) was established by varying
amounts of CaCl2. Recombinant proteins were added to
relaxing and preactivating solutions by buffer exchange using
desalting spin columns (Pierce, Rockford, IL).
2.5. In Vitro Motility Assays. In vitro motility assays were
performed as described previously [5]. Briefly, HMM was
applied to a nitrocellulose-coated coverslip followed by incu-
bation with bovine serum albumin (BSA) to prevent non-
specific adsorption of thin filaments or recombinant proteins
to the motility surface. Shredded actin filaments followed by
ATP were then added to block nonfunctional myosin heads
(dead-heads). Next, rhodamine-phalloidin labeled bovine
cardiac thin filaments (4 : 1 : 1 actin:tropomyosin:troponin)
were added, followed by a motility buffer containing AB
buffer, 2 mM ATP, and an oxygen-scavenging system to
limit photo-bleaching. Recombinant cMyBP-C proteins were
dialyzed into AB buffer and added to the slide surface in
the motility buffer. Motility was viewed using an Olympus
IX-71 microscope with an Hg-arc lamp, TRITC filter, and
a 100×/1.4 NA oil-immersion objective. Video files were
recorded using a Q-Imaging Retiga Exi digital camera and
ImageProPlus software. Filament motility was analyzed using
custom software developed in LabView and NI Vision
Development (National Instruments, Austin, TX) kindly
provided by Dr. Michael Regnier (University of Washington).
2.6. ATPase Assay. ATPase assays were performed by
mixing 0.2 μM myosin S1 and 3.5 μM reconstituted
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Table 2: Primers used to create recombinant chimeric C0C1 proteins.
cMyBP-C domain Primer pairs (upstream/downstream primer)
Mouse C0
5′-ATCACCATCACCATATGCCGGAGCCAGGGAAGAAACCA -3′/
5′-AGGGGCCAGCATGGGTTCTGCCTTCTCTGGAGGGGC -3′
Mouse P/A
5′-TCTGAAGTTGCTCCAGGAGCC -3′/
5′-GTCATCAGGGGCTCCCTGATG -3′
Mouse C1
5′-GGAGCCCCCGATGACCCTATTGGCCTCTTTCTGATGCGA -3′/
5′-TCAGCTAATTAAGCTTTCATCCAGAACCAATCGCCTCATGGAC -3′
Human C0
5′-ATCACCATCACCATATGCCTGAGCCGGGGAAGAAGC - 3′/
5′-TGGAGCAACTTCAGACTCTGCCTTCTCTGCCTCTATGAC -3′
Human P/A
5′-CCCATGCTGGCCCCTGC -3′/
5′-GTCATCGGGGGCTCCAGG -3′
Human C1
5′-GGAGCCCCTGATGACCCCATTGGCCTCTTCGTGATGC -3′/
5′-TCAGCTAATTAAGCTTTCATCCGGTGCCCATGGCCT -3′
bovine cardiac thin filaments (mixed at a 7 : 2 : 2 actin :
tropomyosin : troponin ratio) in ATPase buffer (in mmol/L:
10 imidazole (pH 7.4), 2 MgCl2, 1 EGTA, and 1 DTT)
with or without 1 μM recombinant cMyBP-C proteins. The
addition of 1 mM ATP started the reaction and reactions
were quenched at three different time points with stop
solution (3.3% SDS, 0.12 M Na-EDTA, pH 7.4). Phosphate
production was determined via colorimetric assay as
described [20].
2.7. Statistical Tests. Data were compared using ANOVA
followed by Bonferroni post-hoc comparisons. Significance
was considered at P < .05.
3. Results
3.1. Human C0C1 Increases Ca2+ Sensitivity of Tension in
Permeabilized Trabeculae. Effects of recombinant mouse and
human C0C1 proteins (inclusive of the C0, P/A, and C1
domains) were first assessed in permeabilized rat cardiac
trabeculae. Figure 2(a) shows effects of human (h)C0C1
and mouse (m)C0C1 on force generation at pCa 9.0 and
at maximal Ca2+ activation (pCa 4.5). Neither hC0C1 nor
mC0C1 affected resting force in the absence of Ca2+ (pCa
9.0) or maximal force at pCa 4.5 even at concentrations
up to 80 μM, the highest concentration used by Herron
et al. [7]. This result is consistent with observations by
Razumova et al. [6] who found that preincubation of rat
trabeculae with 30 μM mC0C1 did not affect force, but it
differs somewhat from Herron et al. [7] who found that
30 μM hC0C1 activated force generation even in the absence
of Ca2+ at pCa 9.0. Because measurements by Herron et al.
[7] were conducted primarily using permeabilized myocytes
from human myocardium, species-specific differences (rat
versus human) could potentially contribute to the different
effects observed here. However, as shown in Figures 2(b)
and 2(c), hC0C1 was effective at increasing force and ktr at
submaximal Ca2+ (pCa 5.3) near the half-maximal [Ca2+]
(pCa50) required for maximal force generation [6]. Effects
were significant after preincubation with 50 μM hC0C1.
50 μM mC0C1 also increased Ca2+ sensitivity of tension,
albeit to a lesser extent than hC0C1, but had no effect on ktr.
3.2. The Human Pro-Ala Rich Region Activates Filament
Motility in the Absence of Ca2+. Because results from
permeabilized rat trabeculae suggested that species-specific
differences contribute to differences in effects of hC0C1 and
mC0C1, we sought to compare effects of hC0C1 versus
mC0C1 in a defined system that minimizes variability in
cross-species isoform expression. We therefore compared
effects of hC0C1 and mC0C1 using in vitro motility assays
with reconstituted cardiac thin filaments and skeletal HMM.
Control values for average filament velocities in the absence
(pCa 9) and presence (pCa 5) of Ca2+ were 0.3 ± 0.1 μm/s
(n = 12) and 3.8 ± 0.5 μm/s (n = 9), respectively, demon-
strating that reconstituted thin filaments were well regulated
by Ca2+ under control conditions in the absence of added
recombinant proteins. Figure 3(a) compares filament sliding
speeds at pCa 9.0 in the absence or presence of hC0C1
or mC0C1. Under control conditions at low Ca2+, filament
sliding speed was low and the vast majority of filaments
were stopped (fraction moving was 4%). Addition of 1 μM
mC0C1 to motility buffers did not activate motility, whereas
addition of hC0C1 significantly increased motility. These
results are similar to those obtained in rat trabeculae
(Figure 2) where hC0C1 increased Ca2+ sensitivity of tension
and ktr to a greater extent than mC0C1. They are also
consistent with Herron et al. [7] who found that hC0C1
could activate tension development in myocytes in the
absence of Ca2+.
To determine whether the P/A region contributes to the
activating properties of hC0C1, chimeric C0C1 proteins were
created that substituted human and mouse P/A regions.
Figure 3(b) shows effects on filament motility of exchanging
the human and mouse P/A domains in chimeric proteins.
Insertion of the human P/A region into mouse C0C1 to
create the chimeric protein mhmC0C1 (mouse C0, human
P/A, and mouse C1) increased filament motility at pCa 9.
This result demonstrates that the human P/A region but not
the mouse P/A region is sufficient to confer activating effects
on C0C1 proteins. However, activation was not complete
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Figure 2: Effects of mC0C1 and hC0C1 on steady state force and rate of tension redevelopment (ktr) in permeabilized rat trabeculae. (a)
Preincubation of trabeculae with 80 μM mC0C1 or hC0C1 did not affect resting force at pCa 9.0 or maximal Ca2+ activated force at pCa 4.5.
However, hC0C1 increased force (b) and ktr (c) at intermediate [Ca2+] (pCa 5.3) with effects significant at 50 μM. mC0C1 increased force
at 50 μM but did not significantly increase ktr. Data are mean ± SEM (n = 4 for hC0C1 and n = 3 for mC0C1). Asterisks denote significant
differences in compared values obtained prior to protein addition (P < .05).
since sliding speeds were still somewhat less than in the
presence of hC0C1 comprised of all human sequences. This
suggests that domains outside of the P/A region must also
contribute to the activating effects of hC0C1. Consistent with
this idea, when the mouse P/A region was exchanged into
hC0C1, that is, in hmhC0C1 (human C0, mouse P/A, and
human C1), filament sliding speeds were increased relative
to control but were less than in the presence of hC0C1.
Collectively, these results demonstrate that the human P/A
rich region is sufficient to activate motility in the absence of
Ca2+, but that the C0 or C1 domains must also contribute to
the ability of hC0C1 to activate filament motility.
3.3. Human C1, but not C0, Activates Motility in the Absence
of Ca2+. To determine whether human C1 or C0 domains
also contribute to the activating effects of hC0C1, we created
additional chimeric proteins that substituted human and
mouse C0 and C1 domains. To assess if the C1 domain is
required for activating effects, 1 μM mmhC0C1 or hhmC0C1
proteins were added to in vitro motility assays. As shown
in Figure 3(c), adding the human C1 to mouse C0 and
P/A domains, (mmhC0C1) activated thin filament motility
at pCa 9, demonstrating that the human C1 domain can
also confer activating effects. However, filament velocity was
reduced compared to hC0C1 (Figure 3(a)), indicating that
other domains (e.g., P/A; Figure 3(b)) contribute to the
activating effects of hC0C1. Conversely, when the mouse
C1 domain was added to human C0 and P/A domains
(hhmC0C1) activation occurred but to a lesser extent than
hC0C1 (Figure 3(a)). These results show that mouse C1
cannot substitute for human C1 and cannot restore full
activating effects when expressed with the human C0 and P/A
domains.
To assess whether the human C0 domain also contributes
to activating effects of hC0C1, hmmC0C1 and mhhC0C1
proteins were created and their effects in motility assays
6 Journal of Biomedicine and Biotechnology
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Figure 3: Effects of mouse and human C0, P/A, and C1 domains on motility of regulated thin filaments (F-actin + Tm + Tn) at pCa 9.
(a) Compared to control experiments in the absence of added protein (n = 12), 1 μM hC0C1 significantly activated filament sliding speed
motility and the fraction of filaments moving (n = 8), whereas 1 μM mC0C1 did not affect motility (n = 9). (b) Substitution of the human
for mouse P/A domain in the mouse C0C1 backbone (mhmC0C1) activated motility (n = 7), whereas substitution of the mouse P/A domain
into the human backbone (hmhC0C1) depressed motility relative to hC0C1 (n = 5). (c) Exchange of mouse and human C1 domains. The
human C1 domain (mmhC0C1) activated motility (compared to mC0C1, n = 5), whereas the mouse C1 domain (hhmC0C1) depressed
motility (compared to hC0C1, n = 6). (d) Exchange of mouse and human C0 domains. The human C0 (hmmC0C1, n = 5) and mouse C0
(mhhC0C1, n = 10) domains did not affect thin filament motility (compared to mC0C1 and hC0C1 controls, resp.). Data are mean ± SD.
Asterisks (∗) and crosses (†) denote significant differences compared to mC0C1 and hC0C1, respectively, (P < .05).
were assessed at pCa 9. As shown in Figure 3(d), when the
human C0 domain was added to mouse P/A and C1 domains
(hmmC0C1), activation of filament motility did not occur
and effects of hmmC0C1 were not different from the
parent mC0C1. Similarly, when the mouse C0 domain was
expressed with the human P/A and C1 domains (mhhC0C1),
filament motility was the same as in the presence of hC0C1
(Figure 3(a)). These results show that C0 does not contribute
to the activating effects of hC0C1 in motility assays, and
that the human P/A and C1 domains together are sufficient
to account for the full activating properties of hC0C1 on
actomyosin interactions in the absence of Ca2+.
3.4. Activating Effects Are Independent of Myosin S2. When
expressed in rat neonatal cardiomyocytes, hC0C1 localized
to sarcomere A-bands [7], suggesting that interactions of
hC0C1 with myosin or other thick filament proteins are
required for the observed activating effects. Consistent with
this idea, the C0 domain was reported to bind to myosin
S1 [21] and C1 can bind to myosin S2 [22]. Therefore to
test whether interactions with myosin S2 are required for
the activating effects of the human P/A and C1 domains,
effects of chimeric C0C1 proteins were assessed in ATPase
assays using myosin S1 (without S2) and regulated thin
filaments. As shown in Figure 4, under control conditions in
Journal of Biomedicine and Biotechnology 7
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Figure 4: Effects of mouse and human C0, P/A, and C1 domains
on thin filament activated myosin S1 ATPase assays at pCa 10 in
the absence of myosin S2. 1 μM mC0C1 had no effect on ATPase
activity (n = 9), whereas 1 μM hC0C1 increased ATPase activity (n =
9). The human P/A and C1 domains each activated ATPase activity
(mhmC0C1 (n = 7) and mmhC0C1 (n = 5), resp.) to intermediate
values. The mouse P/A and C1 domains (hmhC0C1, (n = 5) and
hhmC0C1, (n = 6), resp.) depressed ATPase activity when compared
to hC0C1. The human C0 domain (hmmC0C1, n = 6) had no
activating effects on actin-activated S1 ATPase activity, while the
mouse C0 domain (mhhC0C1, n = 4) did not affect activity when
compared to hC0C1. Data are mean± SD. Asterisks (∗) and crosses
(†) denote significant differences when compared to mC0C1 and
hC0C1, respectively, (P < .05).
the absence of recombinant proteins, ATPase rates were low
(0.2 ± 0.2 sec−1, n = 17) at low Ca2+ (pCa 10) and increased
(3.3 ± 1.0 sec−1, n = 16) in the presence of maximal Ca2+
(pCa 3). These results demonstrate that the thin filaments
were well regulated by Ca2+. Similar to the results obtained
in the in vitro motility assays, addition of 1 μM hC0C1
activated ATPase activity at pCa 10, whereas mC0C1 did not
significantly affect ATPase rates. Addition of the human P/A
domain or the C1 domains to the mouse C0C1 backbone
(mhmC0C1 or mmhC0C1) also activated ATPase activity in
the absence of Ca2+, but not to the full extent of hC0C1.
Substituting the mouse P/A and C1 domains in the human
C0C1 backbone (hmhC0C1 and hhmC0C1) reduced ATPase
activity when compared to hC0C1. Similar to motility assays
(Figure 3(d)), exchanging the C0 domains (hmmC0C1 and
mhhC0C1) had no effect on the ATPase rates when compared
to mC0C1 and hC0C1 controls (Figure 4). Taken together,
these results confirm conclusions from the in vitro motility
assays that either the human P/A or C1 domains can confer
activating properties to the hC0C1 protein, but that both
domains are required for full effects. However, because all
activating effects occurred in the absence of myosin S2,
results from the ATPase assays demonstrate that activation
does not require interactions of hC0C1 with myosin S2.
4. Discussion
The major result from this study is that species-specific
differences between mouse and human cMyBP-C contribute
to functional differences in the activities of recombinant
cMyBP-C proteins. In particular, we found significant
sequence divergence (46% identity) in a proline-alanine
(P/A) rich region near the N-terminus of the molecule.
The human P/A rich region but not the mouse P/A region
promoted actomyosin interactions as shown by the ability
of proteins containing the human P/A region to increase
thin filament motility and actomyosin ATPase activity even
in the absence of Ca2+ (Figure 3). Interestingly, the human
C1 domain but not mouse C1 also conferred activating
effects even though the sequences of the C1 domains
are much more similar (90% identity). Taken together,
these results suggest that even modest sequence variations
in conserved domains can lead to significant functional
differences between homologous cMyBP-C proteins.
Results from this study partially reconcile disparate
results from two previously published studies. Using human
cMyBP-C recombinant proteins, Herron et al. [7] attributed
activating effects to the P/A rich region, whereas Razumova
et al. [6], using mouse recombinant proteins, found that the
C1 and M domains together were required to activate force.
In the present study we performed a side-by-side comparison
of the effects of mouse and human C0C1 proteins and found
in good agreement with Herron et al. [7] that the human
P/A region can confer activating effects on actomyosin
interactions, whereas also in good agreement with Razumova
et al. [6] that the mouse P/A region does not. Thus, species-
specific differences can account in part for the different
conclusions reached in the two studies.
The precise mechanism(s) by which the P/A and C1
domains promote actomyosin interactions is not known,
but interactions with either thick filaments [23] or actin
[3] are possible. In support of the former, hC0C1 localizes
to sarcomere A-bands when expressed in rat neonatal
cardiomyocytes [7] and C1 can bind to myosin S2 [22].
However, the present results exclude interactions with thick
filaments because myosin S2 was not required for hC0C1
to increase acto-S1 ATPase activity (Figure 4). Furthermore,
while C0 was reported to bind to myosin S1 [21], C0
made little or no contribution to the activating effects of
hC0C1 (Figures 3 and 4). Thus, interactions with myosin
do not appear important for the activating effects of hC0C1,
although interactions with other thick filament proteins
(e.g., myosin light chains) cannot be excluded. Alternatively,
the P/A region could interact with thin filaments to promote
activation. In support of this idea Squire et al. [24] proposed
that the P/A region of human cMyBP-C binds actin based on
sequence similarity to a P/A rich segment found in essential
myosin light chains (MLC). Although in a previous study
we found little evidence that the mouse P/A region binds
to actin because mC0C1 bound weakly if at all to F-actin in
cosedimentation assays [3], Kulikovskya et al. [25] reported
that human C0C1 can bind actin. Side-by-side comparisons
of binding affinity are needed, but these data are thus in
the right direction for the Pro-Ala sequence to contribute
to functional effects in human (e.g., because of greater actin
binding affinity) but exert less effects in mouse because of
reduced interactions with actin [6, 7].
The functional significance of the Pro-Ala rich sequence
of cMyBP-C in vivo is not known. However, the Pro-Ala
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rich sequences have been identified in other thick filament
regulatory proteins including cardiac and skeletal isoforms of
myosin essential light chains (MLC) [26]. In these proteins
the Pro-Ala sequences modulate cross-bridge cycling rates
and shortening velocity (Vmax) by binding to actin [27].
The proline-alanine rich regions of different MLC isoforms
slow cross-bridge kinetics either by binding directly to actin
[28] or by functioning as a rigid spacer arm that extends
an actin binding site located near the N-terminus of the
MLC out toward the thin filament [29]. In either case,
interactions with actin are thought to create a drag that
limits filament sliding and slows cross-bridge cycling and
shortening velocity [30]. Consistent with this idea, atrial
myocytes that express an atrial MLC isoform with reduced
affinity for actin have nearly twice the Vmax and maximal
power output than ventricular myocytes expressing an MLC
that binds to actin with greater affinity [26].
By analogy with MLC, it is possible that the Pro-
Ala rich region of cMyBP-C performs a similar role and
contributes to the ability of cMyBP-C to limit myocyte
shortening velocity, cross-bridge cycling, and power output
[31]. If so, then the species-specific differences described here
between the Pro-Ala regions of mouse and human cMyBP-
C could serve to fine-tune shortening velocity to optimize
power output (the product of force and velocity) such that
contractile efficiency is maximized in hearts that contract
under different hemodynamic loads and at different speeds.
Consistent with this idea, we found that the percentage of
proline and alanine residues in the Pro-Ala region varies
inversely with heart rate in mammals such that larger
mammals have a greater proportion of Pro-Ala residues,
Shaffer and Harris [32]. Thus, decreased Pro-Ala content of
cMyBP-C in small mammals could accelerate cross-bridge
cycling kinetics, whereas increased Pro-Ala content in larger
mammals could slow cycling rates. Species-specific changes
in cMyBP-C could thereby fine-tune larger shifts in cross-
bridge cycling kinetics that occur due to differences in
isoform expression of other contractile proteins such as
in myosin heavy chain that shifts from fast α-MHC (high
ATPase activity and cross-bridge cycling) expressed in small
mammals to slow β-MHC expressed in larger mammals [33–
36]. Such systematic changes in cross-bridge cycling kinetics
could also tune cardiac relaxation rates, for instance, to
ensure adequate diastolic filling times even at high heart rates
in small mammals.
In summary, results presented here demonstrate signifi-
cant species-specific differences in the ability of the P/A rich
region and C1 domains of mouse versus human cMyBP-C
to activate actomyosin interactions. These differences suggest
that the function of cMyBP-C varies in different species
and raises the intriguing possibility that cMyBP-C-fine-tunes
cardiac contraction in different animals to better match
contractile speed to hemodynamic load. Experiments to test
these ideas are in progress.
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